Quick View
| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥52.5B | ¥50.6B | +3.7% |
| Operating Income | ¥3.0B | ¥2.6B | +13.6% |
| Ordinary Income | ¥3.1B | ¥2.7B | +13.9% |
| Net Income | ¥2.2B | ¥1.6B | +36.4% |
| ROE | 8.1% | 6.3% | - |
Executive Summary
FY2026 Q3 results show moderate growth across all profit lines. Revenue reached 5,249 million yen (YoY +3.7%), Operating Income 298 million yen (YoY +13.6%), Ordinary Income 310 million yen (YoY +13.9%), and Net Income 218 million yen (YoY +36.4%). The company maintained a high gross profit margin of 56.6% while demonstrating improved operating leverage through controlled selling, general and administrative expenses. Net income growth significantly outpaced revenue growth, driven by stable non-operating performance and lower tax burden. The balance sheet expanded to 5,490 million yen in total assets from 5,060 million yen, with equity increasing to 2,710 million yen from 2,530 million yen. Earnings per share reached 20.44 yen for the quarter, while the company forecasts full-year revenue of 6,320 million yen with net income of 75 million yen, representing projected annual growth of 66.1% in net income.
Key Metrics
[Profitability] ROE of 8.1% is calculated from net profit margin of 4.2%, total asset turnover of 0.956, and financial leverage of 2.03 times based on DuPont analysis. Operating margin improved to 5.7% for the period, supported by gross profit margin of 56.6%, indicating strong pricing power and product mix advantages. Interest coverage ratio stands at approximately 30 times, with interest expense of 10 million yen against operating income of 298 million yen, demonstrating ample capacity to service debt obligations. [Cash Quality] Cash and deposits totaled 1,395 million yen, providing coverage of 1.70 times against short-term debt of 820 million yen. Working capital shows deterioration with accounts receivable increasing 43.0% YoY to 838 million yen, and inventory turnover days extended to 96 days, suggesting collection and inventory management challenges. [Investment Efficiency] Total asset turnover of 0.956 reflects moderate asset utilization. Receivables turnover days lengthened significantly due to the 43.0% increase in accounts receivable against 3.7% revenue growth, warranting attention to collection efficiency. [Financial Health] Equity ratio stands at 49.4%, down from 50.0% in the prior year, with current ratio of 182.9% and quick ratio of 150.5% indicating solid short-term liquidity. Debt-to-equity ratio of 1.03 remains within conservative range, though short-term debt represents 61.2% of total liabilities at 820 million yen, creating refinancing concentration risk. Interest-bearing debt totals 1,340 million yen, comprising 820 million yen in short-term borrowings and 520 million yen in long-term debt.
Cash Flow Analysis
Cash and deposits decreased 51 million yen YoY from 1,446 million yen to 1,395 million yen despite net income growth of 36.4%, indicating cash consumption in working capital. The primary driver of cash usage appears to be accounts receivable expansion of 252 million yen (43.0% YoY increase), significantly outpacing revenue growth and suggesting extended payment terms or customer mix changes. Accounts payable increased 68 million yen (27.8% YoY) to 313 million yen, providing partial offset through supplier credit utilization. Long-term borrowings increased 140 million yen (36.8% YoY) to 520 million yen, suggesting debt refinancing or funding for capital allocation. Short-term debt coverage by cash remains adequate at 1.70 times, though the combination of cash decline and working capital expansion indicates potential pressure on operating cash generation. The working capital cycle shows deterioration with inventory turnover at 96 days and receivables collection extending significantly, both factors constraining cash conversion despite profitable operations.
Earnings Quality
Ordinary income of 310 million yen compared to operating income of 298 million yen indicates net non-operating contribution of approximately 12 million yen, representing 0.2% of revenue. Non-operating income totaled 22 million yen, primarily consisting of dividend income and other financial income, while non-operating expenses included interest expense of 10 million yen, resulting in modest net financial income contribution. The non-operating impact is minimal relative to core operating performance, suggesting earnings quality is driven predominantly by business operations. The significant divergence between net income growth of 36.4% and operating income growth of 13.6% reflects lower effective tax burden, with the tax burden coefficient at 0.694. The substantial increase in accounts receivable (43.0% YoY) against moderate revenue growth (3.7% YoY) raises concerns about accruals quality, as revenue recognition may be outpacing cash collection. Inventory turnover days of 96 days combined with receivables expansion suggests working capital is absorbing cash that would otherwise validate reported earnings. While the interest coverage ratio of 30 times demonstrates strong debt servicing capacity, the deterioration in working capital metrics warrants monitoring of cash-backed earnings quality in future periods.
Risk Factors
Working capital deterioration poses the primary risk, with accounts receivable surging 43.0% YoY to 838 million yen while revenue grew only 3.7%, and inventory turnover extending to 96 days. This 252 million yen increase in receivables represents 115% of quarterly net income, indicating potential collection challenges or aggressive revenue recognition that could pressure future cash flows and require additional financing. Short-term debt concentration creates refinancing risk, with 820 million yen in short-term borrowings representing 61.2% of total liabilities and requiring rollover within one year. While current cash coverage of 1.70 times appears adequate, deteriorating operating cash generation could elevate refinancing vulnerability if credit conditions tighten. Operating margin of 5.7% and net profit margin of 4.2% remain below pharmaceutical industry best practices, limiting buffer against adverse events. The low profitability combined with ROE of 8.1% suggests constrained pricing power in certain segments or cost structure challenges that could impair competitiveness during market downturns or regulatory changes affecting pharmaceutical pricing and reimbursement.
Industry Benchmark (Reference - Proprietary Data)
[Industry Position] (Reference - Proprietary Analysis) The company demonstrates significantly stronger performance than pharmaceutical industry medians across multiple dimensions. Profitability metrics substantially exceed industry benchmarks, with Operating Margin of 5.7% versus industry median of -218.2%, Net Profit Margin of 4.2% versus industry median of -216.8%, and ROE of 8.1% versus industry median of -35.8%. This positions the company in the upper quartile of pharmaceutical peers, most of which reported losses during the same period. Financial Health indicators show Equity Ratio of 49.4% below the industry median of 67.8%, suggesting more aggressive use of leverage compared to peers, though still within prudent ranges. Current Ratio of 182.9% falls well below the industry median of 662%, reflecting the company's higher proportion of current liabilities at 61.2% of total liabilities. Efficiency metrics reveal Asset Turnover of 0.956 substantially exceeds the industry median of 0.17, indicating superior asset utilization, while Receivables Turnover Days of approximately 58 days (calculated from 838 million yen receivables and quarterly revenue) compares favorably to industry median of 151.55 days despite recent deterioration. Revenue Growth of 3.7% YoY contrasts sharply with industry median decline of -12.5%, demonstrating relative market share gains or better demand resilience. The company's positive profitability, revenue growth, and efficient asset utilization distinguish it from an industry cohort characterized by widespread losses and revenue contraction. (Industry: Pharmaceutical, N=13 companies for most metrics, Comparison period: 2025-Q3, Source: Proprietary analysis)
Key Takeaways from Earnings
Gross profit margin sustainability at 56.6% represents a key structural advantage, indicating differentiated product positioning or favorable customer contracts that generate premium margins significantly above typical pharmaceutical distribution businesses. This high gross margin provides operating leverage potential, as evidenced by operating income growing 13.6% on revenue growth of only 3.7% through controlled SG&A expenses. The margin structure suggests the Retail and Water Operation divisions contribute disproportionately to profitability, with the Wholesaling Division reporting negative operating income of 4.4 million yen requiring strategic review. Working capital management emerges as the critical near-term determinant of cash flow performance and financial flexibility. The 252 million yen increase in accounts receivable and extended inventory turnover to 96 days collectively represent approximately 350 million yen in incremental working capital consumption, exceeding full-year forecasted net income of 75 million yen. Resolution of working capital efficiency through improved collection processes or inventory optimization would significantly enhance free cash flow generation and reduce dependence on short-term borrowing. Conservative full-year guidance projects net income of 75 million yen against 218 million yen already achieved in Q3 cumulative results, implying potential for upside revision or reflecting seasonal patterns and one-time factors in quarterly results requiring clarification. The disconnect between quarterly run-rate and annual forecast, combined with 66.1% projected annual net income growth, suggests either conservative forecasting or material profit variability across quarters that investors should monitor through segment disclosures and management commentary.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.
AI Financial Analysis
Executive Summary
FY2026 Q3 earnings were strong on a cumulative basis, with modest sales growth translating into faster operating and net-profit growth. Revenue increased 3.7% YoY to ¥5.248bn. Operating income rose 13.6% YoY to ¥298m. Ordinary income increased 13.9% YoY to ¥310m. Net income rose 36.4% YoY to ¥218m, materially outpacing the operating-profit increase. The gross margin declined by approximately 105bp YoY to 56.6%, indicating some pressure in product procurement costs or sales mix. However, the SG&A-to-sales ratio improved by approximately 156bp to 50.9%. This SG&A efficiency more than offset gross-margin pressure and lifted the operating margin by roughly 50bp to 5.7%. The net margin expanded by approximately 101bp to 4.2%, supported by the operating-margin improvement and a lower effective tax rate of 30.6%. Non-operating income was limited at ¥22m, or around 0.4% of revenue, while interest expense of ¥10m remained manageable. A ¥4m gain on sale of non-current assets modestly supported pre-tax income but was not material to the overall earnings result. Annualized ROE was 10.7%, placing returns in the good range, although financial leverage of 2.03x remains a meaningful contributor. Liquidity is sound, with a current ratio of 182.9%, quick ratio of 150.5%, and cash equal to 1.70x short-term loans. The key balance-sheet watchpoints are the 43.0% YoY rise in trade receivables and inventory days of 72 days, which exceeds the 60-day alert threshold. The company has already achieved 83.0% of full-year sales guidance, 248.3% of operating-income guidance, and 290.7% of net-income guidance by Q3. The current full-year forecast therefore appears substantially conservative relative to cumulative Q3 performance and implies a sharply loss-making fourth quarter at the operating and net-income levels if left unchanged. Near-term attention should focus on receivables collection, inventory normalization, refinancing of short-dated borrowings, and the treatment of the full-year earnings forecast.
Profitability Analysis
The annualized DuPont ROE of 10.7% is decomposed into a 4.2% net profit margin, 1.275x asset turnover, and 2.03x financial leverage. The principal positive change in the earnings structure was margin improvement rather than top-line expansion: revenue rose 3.7%, while operating income rose 13.6%. Gross margin declined to 56.6% from approximately 57.7% in the prior period, a deterioration of about 105bp. Conversely, SG&A expenses grew only 0.7% YoY, materially below revenue growth, reducing the SG&A ratio to 50.9% from approximately 52.5%. This operating leverage increased the operating margin to 5.7% from approximately 5.2%, an improvement of around 50bp. The operating margin remains above the 5% concern threshold but below the 8% level generally associated with stronger profitability. Net income grew faster than ordinary income because the effective tax rate fell to 30.6% from approximately 40.8% in the prior period. The tax burden of 0.694 was slightly below the 0.70 normal benchmark, but it was not indicative of an unusually burdensome tax outcome. Interest burden was favorable at 1.055, reflecting non-operating income sufficient to exceed interest expense and an interest coverage ratio of 30.23x. Financial leverage contributes materially to shareholder returns, as the 2.03x leverage factor is substantially larger than the net-margin contribution. The sustainability of the current profit improvement depends on maintaining SG&A discipline while preventing further erosion of the gross margin. The decline in the gross margin is the main operational item to monitor, particularly because the business requires sufficient gross-profit generation to cover a high fixed SG&A base.
Growth Assessment
Revenue growth of 3.7% YoY to ¥5.248bn was modest but positive. Operating income growth of 13.6% and net-income growth of 36.4% demonstrate that earnings growth materially exceeded sales growth. The operating gain was driven by SG&A containment, with SG&A rising only 0.7% YoY versus 3.7% revenue growth. This indicates positive operating leverage in the current cumulative period. Gross profit increased 1.8% YoY to ¥2.970bn, slower than revenue growth, consistent with the lower gross margin. The faster growth in net income also benefited from a lower tax expense, which declined to ¥96m from ¥110m despite higher pre-tax income. Full-year sales guidance of ¥6.320bn implies Q3 progress of 83.0%, 8.0 percentage points above the standard 75% Q3 progress level. Full-year operating-income guidance of ¥120m has already been exceeded by ¥178m, with Q3 progress at 248.3%. Full-year net-income guidance of ¥75m has already been exceeded by ¥143m, with Q3 progress at 290.7%. If the guidance remains unchanged, the implied Q4 outcome is revenue of ¥1.072bn, operating loss of ¥178m, ordinary loss of ¥180m, and net loss of ¥143m. This implied outcome is inconsistent with the cumulative Q3 earnings profile and makes forecast revision or a material Q4 cost/revenue event central to the outlook. Revenue quality should be assessed alongside the sharp increase in receivables, as sales conversion into cash will be important for validating the reported growth.
Financial Health
Liquidity is healthy, with current assets of ¥3.394bn against current liabilities of ¥1.856bn. The current ratio is 182.9% and the quick ratio is 150.5%, both comfortably above conventional warning thresholds. Working capital was positive at ¥1.539bn. Cash and deposits totaled ¥1.395bn, representing 25.4% of total assets and covering short-term loans by 1.70x. Total interest-bearing debt was ¥1.340bn, comprising ¥820m of short-term loans and ¥520m of long-term loans. Debt-to-equity was 1.03x, modestly above the conservative 1.0x benchmark but well below the 2.0x aggressive-leverage warning threshold. Debt-to-capital was 33.1%, within the sub-40% investment-grade benchmark. Interest coverage of 30.23x indicates that the current interest burden is readily serviceable from operating income. Refinancing risk nevertheless warrants attention because 61.2% of interest-bearing debt is short term, exceeding the 40% quality-alert threshold. The elevated short-term debt mix raises dependence on continued access to bank refinancing, although the immediate liquidity position provides a meaningful buffer. Trade receivables increased ¥252m, or 43.0% YoY, to ¥838m, substantially faster than revenue growth. Accounts payable increased ¥68m, or 27.8% YoY, to ¥313m, partially funding the working-capital build. Long-term loans increased ¥140m, or 36.8% YoY, to ¥520m, increasing leverage exposure despite the still-manageable debt metrics. Intangible assets declined ¥30m, or 26.9% YoY, to ¥82m and account for only 1.5% of total assets. Property, plant and equipment represented 30.0% of assets, including land of ¥1.197bn, which provides asset backing but reduces balance-sheet flexibility relative to a more liquid asset base.
Notable B/S Changes
Accounts receivable: +¥252m (+43.0%) to ¥838m - growth substantially exceeded the 3.7% rise in revenue, increasing collection and earnings-conversion risk. Long-term loans: +¥140m (+36.8%) to ¥520m - increased long-term funding supports maturity extension but raises total leverage exposure. Accounts payable: +¥68m (+27.8%) to ¥313m - supplier financing partly offsets the working-capital build, while raising the importance of payment-cycle management. Intangible assets: -¥30m (-26.9%) to ¥82m - the decline reduces intangible-asset exposure; intangible assets represent only 1.5% of total assets.
Cash Flow Quality
The rise in trade receivables and inventories relative to sales is the principal earnings-conversion risk visible in the balance sheet. Trade receivables increased 43.0% YoY while revenue increased only 3.7% YoY, requiring close monitoring of collection timing and credit quality. Inventories increased to ¥601m from ¥506m, while inventory days reached 72 days, above the 60-day quality-alert threshold. The inventory increase may reflect stocking for expected demand or procurement timing, but it also raises the risk of slower turnover, markdowns, or obsolescence. The increase in accounts payable partly offsets the working-capital funding requirement, but this does not remove the need for receivables and inventory to normalize. Cash of ¥1.395bn and positive working capital of ¥1.539bn provide a near-term liquidity buffer against this working-capital pressure.
Dividend Sustainability
The interim dividend was ¥2.50 per share. The calculated interim payout ratio was 13.4% against cumulative Q3 net income of ¥218m, indicating low earnings distribution at this stage. Full-year guidance indicates a ¥5.00 per share dividend and EPS of ¥7.03. On that guidance basis, the full-year dividend payout ratio would be approximately 71.1%, above the 60% sustainability benchmark but below 100%. The interim ¥2.50 payment represents half of the indicated full-year dividend. The sustainability assessment is therefore highly sensitive to the full-year earnings outcome and any revision to the current ¥75m net-income forecast. The balance sheet provides support through ¥1.395bn of cash, but the priority for capital allocation should also account for the elevated short-term debt proportion and working-capital build. Retained earnings increased to ¥1.741bn from ¥1.577bn in the prior period, strengthening internal capital. A dividend level consistent with the current forecast would require a meaningfully higher share of annual earnings than the cumulative Q3 payout ratio suggests.
Risk Assessment
Business risks include Gross-margin risk: gross margin declined approximately 105bp YoY to 56.6%, and further procurement-cost or product-mix pressure would disproportionately affect profitability given the high SG&A base., Working-capital risk: trade receivables increased 43.0% YoY and inventory days reached 72 days, increasing the risk that reported sales and earnings are not converted promptly into liquidity., Inventory risk: finished goods account for essentially all reported inventories at ¥601m; slower demand, expiry, product obsolescence, or discounting could pressure gross profit., Industry-specific healthcare and OTC-product risk: demand can be affected by consumer health trends, seasonal illness patterns, reimbursement or healthcare-policy changes, and price competition in health-related products..
Financial risks include Refinancing risk: short-term debt represents 61.2% of interest-bearing debt, above the 40% alert threshold, creating reliance on debt rollover even though cash coverage is currently solid., Leverage risk: debt-to-equity of 1.03x is manageable but slightly above the conservative benchmark, and long-term loans increased 36.8% YoY., Forecast-risk exposure: Q3 operating income already exceeds full-year guidance by 148.3%, making the eventual treatment of guidance a material source of earnings-expectation volatility..
Key concerns include High inventory days of 72 are the most direct operating quality alert; the underlying cause and expected inventory normalization should be monitored., Receivables grew far more rapidly than revenue, indicating a potential deterioration in cash-conversion efficiency or a shift in billing and collection timing., The earnings improvement relies on SG&A efficiency despite gross-margin compression; a reversal in cost discipline would weaken operating leverage., The implied Q4 result under unchanged guidance is sharply negative, so the full-year forecast requires particular scrutiny..
Investment Implications
Key takeaways include Cumulative Q3 performance was favorable: revenue increased 3.7% YoY, operating income 13.6%, and net income 36.4%., Operating-margin expansion to 5.7% was driven by SG&A leverage, which more than offset a roughly 105bp gross-margin decline., Annualized ROE of 10.7% is supported by a 4.2% net margin, 1.275x asset turnover, and 2.03x financial leverage., Liquidity and interest servicing are strong, but the 61.2% short-term debt ratio makes refinancing structure a relevant risk factor., Receivables growth and 72 inventory days are key tests of the durability and cash conversion of the earnings improvement., The current full-year forecast is substantially below cumulative Q3 operating and net-income results, creating a major outlook and earnings-expectation variable..
Metrics to watch include Gross margin and SG&A-to-sales ratio, Trade receivables growth relative to revenue growth, Inventory days and finished-goods balance, Short-term debt ratio, cash-to-short-term-debt coverage, and long-term loan balance, Operating margin and annualized ROE, Any update to full-year sales, operating-income, ordinary-income, net-income, EPS, and dividend guidance.
Regarding relative positioning, The company exhibits adequate liquidity, strong interest coverage, and an annualized ROE in the good range, but its 5.7% operating margin remains below the stronger 8% profitability benchmark. Its capital structure is more leveraged than a conservative net-cash or sub-1.0x D/E profile, though debt-to-capital remains within a moderate range. Relative earnings quality will depend primarily on whether elevated receivables and inventory normalize while SG&A efficiency is sustained.